Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04017455 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Study acronym: TARZAN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 4 months later Aug 31, 2025 → Dec 31, 2028
See other at-risk trials from The Netherlands Cancer Institute

Record History

  1. Primary and study completion pushed from Aug 31, 2025 to Dec 31, 2028 Eligibility criteria expanded, about 10 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 10 words
  2. Primary completion date: Aug 30, 2023 to Aug 31, 2025 Trial status: Recruiting to Active, Not Recruiting · Completion date: Aug 30, 2024 to Aug 31, 2025 · Site details revisedv5 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Aug 30, 2024 to Aug 31, 2025
    • Site details revised
  3. Study site revisedv4 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 1, 2019 to Oct 22, 2019 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Sep 1, 2019 to Oct 22, 2019
    • Site details revised
  5. Phase: Phase 1/2 to Phase 2 Secondary endpoints: 1 to 2 · Study description shortened, about 10 words · Eligibility criteria expanded, about 3 wordsv2 Show 3 more changesShow less
    • Secondary endpoints: 1 to 2
    • Study description shortened, about 10 words
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Trial Details
NCT Number NCT04017455
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Hoffmann-La Roche
Conditions Rectal Cancer
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov